JP2012502113A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502113A5 JP2012502113A5 JP2011527020A JP2011527020A JP2012502113A5 JP 2012502113 A5 JP2012502113 A5 JP 2012502113A5 JP 2011527020 A JP2011527020 A JP 2011527020A JP 2011527020 A JP2011527020 A JP 2011527020A JP 2012502113 A5 JP2012502113 A5 JP 2012502113A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- administration
- monocytes
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 8
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 8
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 8
- 210000001616 monocyte Anatomy 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 3
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 2
- 108010082786 Interleukin-1alpha Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9656308P | 2008-09-12 | 2008-09-12 | |
| US61/096,563 | 2008-09-12 | ||
| PCT/US2009/056809 WO2010030979A2 (en) | 2008-09-12 | 2009-09-14 | Targeting pathogenic monocytes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012502113A JP2012502113A (ja) | 2012-01-26 |
| JP2012502113A5 true JP2012502113A5 (https=) | 2012-10-11 |
| JP5976319B2 JP5976319B2 (ja) | 2016-08-23 |
Family
ID=42005801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527020A Active JP5976319B2 (ja) | 2008-09-12 | 2009-09-14 | 病原性単球の標的化 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8242074B2 (https=) |
| EP (1) | EP2326347A4 (https=) |
| JP (1) | JP5976319B2 (https=) |
| CN (1) | CN102209557A (https=) |
| AU (1) | AU2009291536B2 (https=) |
| CA (1) | CA2737056C (https=) |
| WO (1) | WO2010030979A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1915620T3 (da) | 2005-08-02 | 2010-10-04 | Xbiotech Inc | Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer |
| WO2007132338A2 (en) * | 2006-05-15 | 2007-11-22 | Xbiotech Inc. | IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS |
| US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| CN102580086A (zh) * | 2006-05-22 | 2012-07-18 | 埃克斯生物科技公司 | 使用抗IL-1α抗体治疗癌症 |
| CA2726345C (en) | 2008-05-30 | 2018-08-28 | John Simard | Interleukin-1 alpha antibodies and methods of use |
| EP2569640A1 (en) | 2010-05-12 | 2013-03-20 | The University of Birmingham | Biomarker |
| KR101539684B1 (ko) | 2010-05-14 | 2015-07-27 | 애브비 인코포레이티드 | Ｉｌ－１ 결합 단백질 |
| AU2015203524B2 (en) * | 2010-06-18 | 2016-10-20 | Xbiotech Inc. | Arthritis treatment |
| KR102167261B1 (ko) | 2010-06-18 | 2020-10-20 | 엑스바이오테크, 인크. | 관절염 치료 |
| AU2015271978B2 (en) * | 2010-08-23 | 2017-10-26 | Xbiotech Inc. | Treatment for neoplastic diseases |
| US10294296B2 (en) | 2010-08-23 | 2019-05-21 | Xbiotech, Inc. | Treatment for neoplastic diseases |
| JP6062918B2 (ja) * | 2011-04-01 | 2017-01-18 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 皮膚科的病理の治療 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| CN107759690A (zh) * | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| CA3053231A1 (en) | 2017-02-16 | 2018-08-23 | Xbiotech Inc. | Treatment of hidradenitis suppurativa |
| US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
| CA3095740A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin alpha (il-1a) |
| CA3095676A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095675A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleukin 1 alpha (il-1a) |
| CA3095679A1 (en) | 2020-10-07 | 2022-04-07 | Xbiotech Inc. | True human antibody specific for interleuken 1 alpha (il-1a) |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| JPS6040858A (ja) * | 1983-08-15 | 1985-03-04 | Nissan Motor Co Ltd | 自動変速機の油圧制御装置 |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US5034316A (en) | 1987-03-30 | 1991-07-23 | The Regents Of The University Of California | In vitro human monoclonal IgG rheumatoid factor autoantibody |
| BR8907457A (pt) * | 1988-05-27 | 1991-04-02 | Synergen Inc | Inibidores de interleucina-1 |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| CA2147151A1 (en) | 1992-10-14 | 1994-04-28 | Robert A. Snow | Therapeutic and diagnostic imaging compositions and methods |
| ES2159529T5 (es) | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
| US5959085A (en) | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| EP0659766A1 (en) * | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9509620D0 (en) | 1995-05-12 | 1995-07-05 | Nat Blood Authority | Transepithelial transport of molecular species |
| WO1997002479A2 (en) | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| US20030040617A9 (en) | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US6623736B2 (en) | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| KR100919593B1 (ko) * | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물 |
| US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| AU2002355553A1 (en) * | 2001-08-07 | 2003-02-24 | Corporation For National Research Initiatives | An electromechanical switch and method of fabrication |
| US7030126B2 (en) * | 2001-11-16 | 2006-04-18 | Als Therapy Development Foundation, Inc. | Use of polyamine analogs for amyotrophic lateral sclerosis |
| CA2824167C (en) * | 2002-09-06 | 2018-09-25 | Amgen Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
| US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7799327B2 (en) | 2003-12-24 | 2010-09-21 | Henry John Smith | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US20050276807A1 (en) | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
| WO2006036936A2 (en) | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
| PL1819359T3 (pl) | 2004-12-09 | 2015-08-31 | Janssen Biotech Inc | Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie |
| DK1915620T3 (da) | 2005-08-02 | 2010-10-04 | Xbiotech Inc | Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN101267834B (zh) | 2005-09-28 | 2013-06-05 | 赛托斯生物技术公司 | 白介素-1偶联物及其用途 |
| WO2007132338A2 (en) * | 2006-05-15 | 2007-11-22 | Xbiotech Inc. | IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS |
| CN102580086A (zh) | 2006-05-22 | 2012-07-18 | 埃克斯生物科技公司 | 使用抗IL-1α抗体治疗癌症 |
| ES2567402T3 (es) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos |
| WO2008082651A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
| WO2009128934A1 (en) | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
| CA2726345C (en) | 2008-05-30 | 2018-08-28 | John Simard | Interleukin-1 alpha antibodies and methods of use |
| SG172855A1 (en) | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
-
2009
- 2009-09-14 AU AU2009291536A patent/AU2009291536B2/en active Active
- 2009-09-14 CN CN2009801446182A patent/CN102209557A/zh active Pending
- 2009-09-14 JP JP2011527020A patent/JP5976319B2/ja active Active
- 2009-09-14 WO PCT/US2009/056809 patent/WO2010030979A2/en not_active Ceased
- 2009-09-14 US US12/559,019 patent/US8242074B2/en active Active
- 2009-09-14 EP EP09813742A patent/EP2326347A4/en active Pending
- 2009-09-14 CA CA2737056A patent/CA2737056C/en active Active
-
2012
- 2012-07-10 US US13/545,166 patent/US8546331B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502113A5 (https=) | ||
| Wakefield et al. | Scleritis: immunopathogenesis and molecular basis for therapy | |
| Flossmann et al. | Deoxyspergualin in relapsing and refractory Wegener's granulomatosis | |
| EP2987807A3 (en) | Antibodies recognising phospho-tau | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| JP2009539841A5 (https=) | ||
| EA200971130A1 (ru) | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний | |
| JP2013501814A5 (https=) | ||
| EA201370105A1 (ru) | Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a) | |
| WO2008002933A3 (en) | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof | |
| MA38276A1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| EP2753348A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE | |
| JP2014523906A5 (https=) | ||
| JP2010532761A5 (https=) | ||
| MY157564A (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
| JP2011225596A5 (https=) | ||
| EP2478901A3 (en) | Neurogenic compounds | |
| UA114699C2 (uk) | Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою | |
| PH12012501743A1 (en) | Antigen binding proteins specific for serum amyloid p component | |
| WO2007087557A3 (en) | Surface-layer protein coated microspheres and uses thereof | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| EA201171352A1 (ru) | Антигенсвязывающие фрагменты антитела и их применение для лечения или диагностики глазных болезней | |
| JP2013147495A5 (https=) |